Hemab Therapeutics Holdings (COAG) Insider & Congress Trades

Smart money at a glance

Filings to Oct 31, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 3 added, 0 cutMore adding

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about COAG filings

Are insiders buying or selling Hemab Therapeutics Holdings, Inc. Common Stock (COAG) stock?

Neither. Hemab Therapeutics Holdings, Inc. Common Stock (COAG) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded COAG recently?

None. No member of Congress disclosed a COAG trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this COAG smart-money data?

This summary uses filings available on Oct 31, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on COAG

Lean long2 sources:
- Insiders
- Funds

Top traders
No tracked positions at the last update
Insiders
Lean long3 buys · $2M
Form 4 filings, open market.
Politicians
No recent politician filings found
Funds
Lean long3 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about COAG filings

Are insiders buying or selling Hemab Therapeutics Holdings, Inc. Common Stock (COAG) stock?

Neither. Hemab Therapeutics Holdings, Inc. Common Stock (COAG) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded COAG recently?

None. No member of Congress disclosed a COAG trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this COAG smart-money data?

Funds

What funds are doing

3 moves · 6 mo

Buys/Adds$188.6M

Buys/Adds (3)

FM
FMR LLC
Q2 2026 13F
$135.8M
bought
Signals like this: n=3224, 54% finished lower at D15, median -0.8% vs SPY -0.4%
JC
JPMorgan Chase
Q2 2026 13F
$42.3M
bought
BR
BlackRock
Q2 2026 13F
$10.4M
bought

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 11, 2026

Earnings came in 2.0% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 11, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.80+2.04% beat

-$0.82 expected

Revenue

$0.00

Yahoo Finance

EPS and revenue: Yahoo Finance

Next report

Estimated report: Nov 10, 2026, in 10 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 11, 2026	-$0.80est. -$0.82	+2.04%beat	$0.00Yahoo Finance	No year-ago quarter
Mar 31, 2026Reported May 21, 2026	Not on file	No estimate	$0.00Yahoo Finance	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $40.34
52-wk high: $55.42
High: $42.85
52-wk low: $18.00
Low: $39.38
Prev close: $40.42
Mkt cap: $1.89B
ROE: -47.0%
P/B: 4.0x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $1.9B

Valuation

P/B3.96

Quality

Operating margin0.0%
ROE-47.0%
ROA-30.1%

Growth

Technicals

Price structure

This stock is trending upward, and looks overbought after a fast run-up.

Trend

Constructive

60 / 100

RSI 14

79overbought

20D volatility

74%annualized

52-week range

$41.45

$18.00$55.42

20D support

$27.38recent floor

20D resistance

$42.85recent ceiling

Returns

5D +20.5%20D +33.2%60D -20.5%

Price vs moving averages

SMA20 +24.0%SMA50 +9.4%

Volume pace

0.70xvs prior 20D

Smart money at a glance

Filings to Oct 31, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 3 added, 0 cutMore adding

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about COAG filings

Are insiders buying or selling Hemab Therapeutics Holdings, Inc. Common Stock (COAG) stock?

Neither. Hemab Therapeutics Holdings, Inc. Common Stock (COAG) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded COAG recently?

None. No member of Congress disclosed a COAG trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this COAG smart-money data?

13F: filed up to 45 days late.

Smart money on COAG

Lean long2 sources:
- Insiders
- Funds

Top traders
No tracked positions at the last update
Insiders
Lean long3 buys · $2M
Form 4 filings, open market.
Politicians
No recent politician filings found
Funds
Lean long3 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about COAG filings

Are insiders buying or selling Hemab Therapeutics Holdings, Inc. Common Stock (COAG) stock?

Neither. Hemab Therapeutics Holdings, Inc. Common Stock (COAG) insiders filed no open-market purchases or sales in the 90 days to Oct 31, 2026, according to SEC Form 4 filings.

Which members of Congress have traded COAG recently?

None. No member of Congress disclosed a COAG trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this COAG smart-money data?

Funds

What funds are doing

3 moves · 6 mo

Buys/Adds$188.6M

Buys/Adds (3)

FM
FMR LLC
Q2 2026 13F
$135.8M
bought
Signals like this: n=3224, 54% finished lower at D15, median -0.8% vs SPY -0.4%
JC
JPMorgan Chase
Q2 2026 13F
$42.3M
bought
BR
BlackRock
Q2 2026 13F
$10.4M
bought

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 11, 2026

Earnings came in 2.0% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 11, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.80+2.04% beat

-$0.82 expected

Revenue

$0.00

Yahoo Finance

EPS and revenue: Yahoo Finance

Next report

Estimated report: Nov 10, 2026, in 10 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 11, 2026	-$0.80est. -$0.82	+2.04%beat	$0.00Yahoo Finance	No year-ago quarter
Mar 31, 2026Reported May 21, 2026	Not on file	No estimate	$0.00Yahoo Finance	No year-ago quarter

Open: $40.34
52-wk high: $55.42
High: $42.85
52-wk low: $18.00
Low: $39.38
Prev close: $40.42
Mkt cap: $1.89B
ROE: -47.0%
P/B: 4.0x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $1.9B

Valuation

P/B3.96

Quality

Operating margin0.0%
ROE-47.0%
ROA-30.1%

Growth

Technicals

Price structure

This stock is trending upward, and looks overbought after a fast run-up.

Trend

Constructive

60 / 100

RSI 14

79overbought

20D volatility

74%annualized

52-week range

$41.45

$18.00$55.42

20D support

$27.38recent floor

20D resistance

$42.85recent ceiling

Returns

5D +20.5%20D +33.2%60D -20.5%

Price vs moving averages

SMA20 +24.0%SMA50 +9.4%

Volume pace

0.70xvs prior 20D

Hemab Therapeutics Holdings, Inc. Common Stock

Smart money at a glance

What do analysts expect?

Questions about COAG filings

Smart money on COAG

Questions about COAG filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 2.0% above what analysts expected.

Estimated report: Nov 10, 2026, in 10 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Hemab Therapeutics Holdings, Inc. Common Stock

Smart money at a glance

What do analysts expect?

Questions about COAG filings

Smart money on COAG

Questions about COAG filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 2.0% above what analysts expected.

Estimated report: Nov 10, 2026, in 10 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Hemab Therapeutics Holdings, Inc. Common Stock

Overview

Questions about COAG filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Hemab Therapeutics Holdings, Inc. Common Stock

Overview

Questions about COAG filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.